Beta-cell Death and/or Stress Biomarkers in Diabetes Mellitus Type 1
DOI:
https://doi.org/10.36320/ajb/v11.i1.8030Keywords:
Type 1 diabetes, Beta cells stress , deathAbstract
Diabetes Mellitus type 1 (T1D) occurs due to disturbance intolerance of the immune system and invasion of β-cells by auto-reactive immune T cells and inducing deterioration of β-cells activity and viability and a prolong therapy with external insulin. This study was aimed to detect the predictive power as well as the degree of correlation of defined glutamic acid decarboxylase autoantibody (GADA), protein tyrosine phosphatase type A2 (IA-2A) and total antioxidant capacity (TAC) biomarkers on β-cells stress and/or death in T1D individuals as well as their first degree relatives (FDRs). Three groups of T1D patients, FDRs and apparently diseases free subjects had been enrolled in this work and evaluated for their serum GADA, IA-2A, C-peptide and TAC. The results revealed positive GADA and IA-2A in 88.6% and 40%, respectively, of T1D patients. The frequency of normal level and mean titer of C-peptide were significantly low among T1D and their FDRs, also the frequency of normal level and mean titer of TAC was significantly low among T1D patients. However, no significant difference in C-peptide level was noticed between the GADA+ and GADA- subjects with no significant effect of TAC level on the concentration of C-peptide. Finally, the concentration of C-peptide was significantly lower in IA-2-A positive than IA-2-A negative individuals. In conclusion, GADA, IA-2A and C-peptide combination can suggest the most powerful and cost-effective diagnostic approach in patients with T1D and their FDRs. In addition, IA-2A in T1D patient’s serum can be predicted for β-cell death and/or stress, however, GADA and TAC was found of no effect on the C-peptide level.
Downloads
References
Lehuen A, Diana J, Zaccone P and Cooke A. Immune cell crosstalk in type 1 diabetes. Nat. Rev. Immunol, 2010; 10(7): 501–513.
Raghavendra GM, Emily KS, Farooq S and Carmella E. Biomarkers of β-Cell Stress and Death in Type 1 Diabetes. Curr Diab Rep, 2016; 16(10): 95.
Atkinson MA, Bluestone JA, Eisenbarth GS, Hebrok M, Herold KC, Accili D, Pietropaolo M, Arvan PR, Von Herrath M, Markel DS and Rhodes CJ. How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes, 2011; 60(5): 1370–1379.
Lebastchi J and Herold CK. Immunologic and Metabolic Biomarkers of β-Cell Destruction in the Diagnosis of Type 1 Diabetes. Cold Spring Harb. Perspect. Med, 2012; 2(6): 1-13.
Wenzlau MJ and Hutton CJ. Novel Diabetes Autoantibodies and Prediction of Type 1 Diabetes, Curr. Diab. Rep, 2013; 13(5): 1-14.
Moussa SA. Oxidative Stress in Diabetes Mellitus. Romanian J. Biophys, 2008; 18(3): 225–236.
Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark A, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM and Ziegler A. Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care, 2015; 38(10): 1964–1974.
Butler AE, Cao-Minh L, Galasso R, Rizza RA, Corradin A, Cobelli C and Butler PC. Adaptive changes in pancreatic beta cell fractional area and beta cell turnover in human pregnancy. Diabetologia, 2010; 53(10): 2167–2176.
Wahren J, Kallas Å and Sima AF A. The Clinical Potential of C-Peptide Replacement in Type 1 Diabetes. Diabetes, 2012; 61(4): 761-772.
Shetty V, Jain HR, Singh G, Parekh S, and Shetty S. C-peptide Levels in Diagnosis of Diabetes Mellitus: A Case-control Study. International Journal of Scientific Study, 2017; 4(11): 7-13.
Mahdi NK, Al-Abadi HL, Al-Naama LM, Mahdi JK and Alawy M. The Role of Autoantibody and Antioxidant Enzymes in Patients with Type I Diabetes. Medical Journal of Islamic World Academy of Sciences, 2015; 23(1): 16-23.
Mathis D and Benoist C. Back to central tolerance. Immunity, 2004; 20: 509–516.
Damanhouri LH, Dromey JA, Christie MR, Nasrat HA, Ardawi MS, Robins RA and Todd I. Autoantibodies to GAD and IA-2 in Saudi Arabian patients with diabetes. Diabet Med, 2005; 22(4): 448-452.
Chang YH, Shiau MY, Tsai ST and Lan MS. Autoantibodies against IA-2A, GAD and topoisomerase II in type 1 patients with diabetes. Biochemical and Biophysical research communications, 2004; 320: 802-809.
Regnell SE and Lernmark Å. Early prediction of autoimmune (type 1) diabetes. Diabetologia, 2017; 60(8): 1370–1381.
Couper JJ, Haller MJ, Ziegler AG, Knip M, Ludvigsson J and Craig ME. ISPAD Clinical Practice Consensus Guidelines 2014 Compendium. Phases of type 1 diabetes in children and adolescents. Pediatr Diabetes, 2014; 15(20): 18–25.
Knip M, Korhonen S, Kulmala P, Veijola R, Reunanen A, Raitakari OT, Viikari J, and Akerblom HK. Prediction of type 1 diabetes in the general population. Diabetes Care, 2010; 33(6): 1206–1212.
Tsai EB, Sherry NA, Palmer JP and Herold KC. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia, 2006; 49(2): 261–270.
Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Matheson D, and Skyler JS. Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care, 2008; 31(11): 2188–2192.
Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D and Skyler JS. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care, 2006; 29(3): 643–649.
Varvarovská J, Racek J, Šteˇtina R, Sýkora J, Pomahacˇová R, Rušavý Z, Lacigová S, Trefil L, Siala K, and Stožický F. Aspects of oxidative stress in children with Type 1 diabetes mellitus. Biomedicine & Pharmacotherapy, 2004; 58(10): 539–545.
Hisalkar PJ, Patne AB, Fawade MM and Karnik AC. Evaluation of plasma superoxide dismutase and glutathione peroxidase in type 2 patients. Biology and medicine, 2012; 4(2): 65-72.
Dincer Y, Akcay T, Alademir Z and Ilkova H. Effect of oxidative stress on glutathione pathway in RBCs from patients with IDDM. Metabolism, 2002; 51(10): 1360-1362.
Kural A, Toker A, Seval H, Döventaş Y, Basınoğlu F, Koldaş M, and Sağlam ZA. Advanced Glycation End–Products and Advanced Oxidation Protein Products in Patients with Insulin Dependent Diabetes Mellitus and First Degree Relatives. Medical Journal of Bakırköy, 2011; 7(4): 130-135.
Sabbah E, Savola K, Kulmala P, Veijola R, Vahasalo P, Karjalainen J, Åkerblom HK and Knip M: Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes. The Childhood Diabetes In Finland Study Group. J Clin Endocrinol Metab, 1999; 84(5): 1534–1539.
Decochez K, Keymeulen B, Somers G, Dorchy H, Leeuw HD, Mathieu C, Rottiers R, Winnock F, Elst KV, Weets I, Kaufman L, Pipeleers DG and Gorus FK. Use of an Islet Cell Antibody Assay to Identify Type 1 Diabetic Patients with Rapid Decrease in C-Peptide Levels after Clinical Onset. Belgian Diabetes Registry. Diabetes Care, 2000; 23(8): 1072–1078.
Ten KQ, Aanstoot HJ, Birnie E, Veeze H, and Mul D. GADA Persistence and Diabetes Classification. Lancet Diabetes Endocrinol, 2016; 4(7): 563-564.
Christie MR, Mølvig J, Hawkes CJ, Carstensen B, Mandrup PT and Canadian-European Randomised Control Trial Group. IA-2 Antibody–Negative Status Predicts Remission and Recovery of C-Peptide Levels in Type 1 Diabetic Patients Treated With Cyclosporin. Diabetes Care, 2002; 25(7): 1192-1197.
Cai T, Hirai H, Zhang G, Zhang M, Takahashi N, Kasai H, Satin LS, Leapman RD, and Notkins AL. Deletion of IA-2 and/or IA-2β Decreases Insulin Secretion by Reducing the Number of Dense Core Vesicles, Diabetologia, 2011 ; 54(9): 2347–2357.
Herawati E, Susanto A, and Sihombing CN. Autoantibodies in Diabetes Mellitus. Molecular and Cellular Biomedical Sciences, 2017; (1) 2: 58-64.
Keane KN, Cruzat VF, Carlessi R, de Bittencourt PI Jr, and Newsholme P. Molecular events linking oxidative stress and inflammation to insulin resistance and beta-cell dysfunction. Oxid Med Cell Longev, 2015; 2015: 181643.
Zraika S, Aston-Mourney K, Laybutt DR, Kebede M, Dunlop ME, Proietto J, and Andrikopoulos S. The influence of genetic background on the induction of oxidative stress and impaired insulin secretion in mouse islets. Diabetologia, 2006; 49: 1254–1263.
Bashan N, Kovsan J, Kachko I, Ovadia H, and Rudich A. Positive and Negative Regulation of Insulin Signaling by Reactive Oxygen and Nitrogen Species. Physiol Rev, 2009; 89(1): 27–71.
Leloup C, Tourrel-Cuzin C, Magnan C, Karaca M, Castel J, Carneiro L, Colombani AL, Ktorza A, Casteilla L, and Penicaud L. Mitochondrial reactive oxygen species are obligatory signals for glucose-induced insulin secretion. Diabetes, 2009; 58(3): 673–681.
Llanos P, Contreras-Ferrat A, Barrientos G, Valencia M, Mears D, and Hidalgo C. Glucose-dependent insulin secretion in pancreatic beta-cell islets from male rats requires Ca2+ release via ROS-stimulated ryanodine receptors. PLoS One, 2015; 10: e0129238.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Madha Mohammed Sheet, Hasan Abd Ali Khudhair
This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.
